Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
03 nov. 2023 12h00 HE
|
Xilio Therapeutics, Inc.
Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types,...
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
31 oct. 2023 09h15 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
27 sept. 2023 17h02 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
05 sept. 2023 08h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
05 sept. 2023 07h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
14 août 2023 07h30 HE
|
Xilio Therapeutics, Inc.
Xilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®), in patients with...
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
03 août 2023 16h05 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
25 mai 2023 17h01 HE
|
Xilio Therapeutics, Inc.
Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer Favorable preliminary safety profile for XTX101 observed at the recommended...
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
09 mai 2023 07h30 HE
|
Xilio Therapeutics, Inc.
Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1 safety, PK, PD, and anti-tumor activity data for XTX101, a tumor-activated, Fc-enhanced...
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 avr. 2023 16h05 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...